BiotechTube

AZD5148 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridioides Difficile Infection

Conditions

Clostridioides Difficile Infection

Trial Timeline

Oct 31, 2024 → Dec 25, 2025

NCT ID
NCT06639997

About AZD5148 + Placebo

AZD5148 + Placebo is a phase 1 stage product being developed by AstraZeneca for Clostridioides Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT06639997. Target conditions include Clostridioides Difficile Infection.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT06639997Phase 1Completed
NCT06469151Phase 1Completed

Competing Products

7 competing products in Clostridioides Difficile Infection

See all competitors
ProductCompanyStageHype Score
AZD5148AstraZenecaPhase 2
52
C.difficile vaccinePfizerPhase 3
76
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
74
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
74
REC-3964Recursion PharmaceuticalsPhase 2
47
SER-109Seres TherapeuticsPre-clinical
15
SER-109Seres TherapeuticsPhase 3
69

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85